{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:49:39Z","timestamp":1786740579235,"version":"build-2736575974"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013362","name":"Swiss Cancer Research","doi-asserted-by":"publisher","award":["KFS-6323-02-2025"],"award-info":[{"award-number":["KFS-6323-02-2025"]}],"id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.trecan.2026.07.006","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:16:52Z","timestamp":1786493812000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostate cancer: evading immunity, inspiring therapy"],"prefix":"10.1016","author":[{"given":"Bianca","family":"Cal\u00ec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Brina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Moscarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bressan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Alimonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.07.006_bb0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.trecan.2026.07.006_bb0010","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2026.07.006_bb0015","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/pros.22849","article-title":"Mutational landscape of candidate genes in familial prostate cancer","volume":"74","author":"Johnson","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.trecan.2026.07.006_bb0020","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41568-020-0267-9","article-title":"Prostate carcinogenesis: inflammatory storms","volume":"20","author":"de Bono","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2026.07.006_bb0025","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41588-017-0027-2","article-title":"An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer","volume":"50","author":"Chen","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trecan.2026.07.006_bb0030","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1126\/science.abf8403","article-title":"Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis","volume":"374","author":"Pernigoni","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.07.006_bb0035","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1038\/s41467-024-45332-w","article-title":"The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids","volume":"15","author":"Lachance","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.07.006_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004191","article-title":"Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer","volume":"10","author":"Terrisse","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.07.006_bb0045","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrc2090","article-title":"Inflammation in prostate carcinogenesis","volume":"7","author":"De Marzo","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2026.07.006_bb0050","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature14395","article-title":"Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy","volume":"521","author":"Shalapour","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.07.006_bb0055","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature08782","article-title":"B-cell-derived lymphotoxin promotes castration-resistant prostate cancer","volume":"464","author":"Ammirante","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.07.006_bb0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrurol.2017.167","article-title":"The inflammatory microenvironment and microbiome in prostate cancer development","volume":"15","author":"Sfanos","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0065","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ccell.2023.05.016","article-title":"Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.07.006_bb0070","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","article-title":"Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance","volume":"623","author":"Guo","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.07.006_bb0075","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1158\/0008-5472.CAN-12-3981","article-title":"CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer","volume":"73","author":"Xu","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.07.006_bb0080","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.07.006_bb0085","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.trecan.2023.07.011","article-title":"Genitourinary cancer neoadjuvant therapies: current and future approaches","volume":"9","author":"Nair","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2026.07.006_bb0090","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0095","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0100","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju268","article-title":"Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer","volume":"106","author":"Fong","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.trecan.2026.07.006_bb0105","article-title":"Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: modulating the cold tumor microenvironment","volume":"6","author":"Nair","year":"2025","journal-title":"Med (New York, NY)"},{"key":"10.1016\/j.trecan.2026.07.006_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010851","article-title":"Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer","volume":"13","author":"Lassoued","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.07.006_bb0115","article-title":"Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: a randomized phase I trial","volume":"7","author":"Ager","year":"2026","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.trecan.2026.07.006_bb0120","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","article-title":"Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial","volume":"29","author":"Shenderov","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.07.006_bb0125","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1080\/17512433.2021.1949287","article-title":"Targeting the spectrum of immune checkpoints in prostate cancer","volume":"14","author":"Sena","year":"2021","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0130","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.07.006_bb0135","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3389\/fonc.2019.01287","article-title":"Genomic alteration burden in advanced prostate cancer and therapeutic implications","volume":"9","author":"Ryan","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0140","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0145","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41467-021-21615-4","article-title":"Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling","volume":"12","author":"Brady","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.07.006_bb0150","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1158\/2159-8290.CD-24-0559","article-title":"Androgen receptor inhibition increases MHC class I expression and improves immune response in prostate cancer","volume":"15","author":"Chesner","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.07.006_bb0155","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0160","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","article-title":"NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy","volume":"28","author":"Guerra","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2026.07.006_bb0165","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1172\/JCI200422206","article-title":"Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer","volume":"114","author":"Wu","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2026.07.006_bb0170","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0175","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.celrep.2014.08.044","article-title":"Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity","volume":"9","author":"Toso","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2026.07.006_bb0180","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/2159-8290.CD-19-1352","article-title":"Chromatin regulator CHD1 remodels the immunosuppressive tumor microenvironment in PTEN-deficient prostate cancer","volume":"10","author":"Zhao","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.07.006_bb0185","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","article-title":"Targeting YAP-dependent MDSC infiltration impairs tumor progression","volume":"6","author":"Wang","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.07.006_bb0190","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1128\/MCB.00090-14","article-title":"Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression","volume":"34","author":"Garcia","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0195","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0200","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1479-5876-12-30","article-title":"Tumor infiltrating B-cells are increased in prostate cancer tissue","volume":"12","author":"Woo","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.trecan.2026.07.006_bb0205","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2404916121","article-title":"Peripheral-derived regulatory T cells contribute to tumor-mediated immune suppression in a nonredundant manner","volume":"121","author":"Hossain","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2026.07.006_bb0210","article-title":"Characteristics of tertiary lymphoid structures in prostate cancer and the impact of neoadjuvant therapy on their formation and maturation","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0215","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s41416-022-02085-x","article-title":"Stromal cells in prostate cancer pathobiology: friends or foes?","volume":"128","author":"Pederzoli","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2026.07.006_bb0220","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0225","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41585-023-00739-w","article-title":"Vaccines as treatments for prostate cancer","volume":"20","author":"Rastogi","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0230","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","article-title":"Efficacy and safety of autologous dendritic cell-based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: the VIABLE phase 3 randomized clinical trial","volume":"8","author":"Vogelzang","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0235","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1470-2045(25)00566-2","article-title":"Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial","volume":"27","author":"Fizazi","year":"2026","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0240","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.annonc.2025.05.008","article-title":"Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study","volume":"36","author":"Gratzke","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0245","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO-24-01283","article-title":"Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial","volume":"43","author":"Petrylak","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0250","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 Trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0255","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.annonc.2025.05.007","article-title":"Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study","volume":"36","author":"Graff","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0260","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial","volume":"28","author":"Powles","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.07.006_bb0265","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1470-2045(25)00209-8","article-title":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial","volume":"26","author":"Agarwal","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0270","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0275","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0280","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.6_suppl.72","article-title":"Chimeric antigen receptor (CAR+) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)","volume":"31","author":"Slovin","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0285","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.07.006_bb0290","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.07.006_bb0295","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.07.006_bb0300","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.annonc.2024.09.004","article-title":"Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial","volume":"35","author":"van Wilpe","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0305","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1200\/JCO-24-02637","article-title":"Nivolumab and ipilimumab for metastatic castration-resistant prostate cancer with an immunogenic signature: the multicenter, two-cohort, phase II NEPTUNES study","volume":"43","author":"Leone","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0310","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.07.006_bb0315","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/pros.24110","article-title":"Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: a phase-2 nonrandomized clinical trial","volume":"81","author":"Shenderov","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.trecan.2026.07.006_bb0320","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40425-018-0351-9","article-title":"Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors","volume":"6","author":"Nayak-Kapoor","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.07.006_bb0325","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-026-01619-x","article-title":"A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer","author":"Chandran","year":"2026","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.trecan.2026.07.006_bb0330","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s10637-012-9869-8","article-title":"Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer","volume":"31","author":"Pienta","year":"2013","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.trecan.2026.07.006_bb0335","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ijc.10713","article-title":"Prostate stem cell antigen: identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients","volume":"102","author":"Kiessling","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2026.07.006_bb0340","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.clim.2005.12.008","article-title":"Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer","volume":"120","author":"Elkord","year":"2006","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0345","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1158\/1078-0432.CCR-22-3743","article-title":"Immunogenomic landscape of neuroendocrine prostate cancer","volume":"29","author":"Bhinder","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.07.006_bb0350","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.4049\/jimmunol.177.10.7398","article-title":"CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients","volume":"177","author":"Miller","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0355","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1158\/1078-0432.CCR-07-0842","article-title":"CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer","volume":"13","author":"Kiniwa","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.07.006_bb0360","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ccell.2023.02.017","article-title":"B cells in the tumor microenvironment: multi-faceted organizers, regulators, and effectors of anti-tumor immunity","volume":"41","author":"Laumont","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.07.006_bb0365","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12967-020-02370-4","article-title":"Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer","volume":"18","author":"Ryan","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.trecan.2026.07.006_bb0370","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.07.006_bb0375","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.ccell.2023.10.006","article-title":"Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer","volume":"41","author":"Hawley","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.07.006_bb0380","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","article-title":"Androgen receptor activity in T cells limits checkpoint blockade efficacy","volume":"606","author":"Guan","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.07.006_bb0385","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.07.006_bb0390","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41591-021-01244-6","article-title":"Transcriptional mediators of treatment resistance in lethal prostate cancer","volume":"27","author":"He","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.07.006_bb0395","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.07.006_bb0400","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.07.006_bb0405","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0410","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/ITT.S122497","article-title":"Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer","volume":"6","author":"Scholz","year":"2017","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.trecan.2026.07.006_bb0415","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/(SICI)1097-0045(19990401)39:1<54::AID-PROS9>3.0.CO;2-U","article-title":"Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment","volume":"39","author":"Murphy","year":"1999","journal-title":"Prostate"},{"key":"10.1016\/j.trecan.2026.07.006_bb0420","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymthe.2005.02.012","article-title":"GM-CSF gene-transduced tumor vaccines","volume":"12","author":"Eager","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2026.07.006_bb0425","doi-asserted-by":"crossref","first-page":"18192","DOI":"10.18632\/oncotarget.4145","article-title":"Phase I\/II clinical trial of dendritic-cell based immunotherapy (DCVAC\/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer","volume":"6","author":"Podrazil","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2026.07.006_bb0430","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-0045(19970201)30:2<73::AID-PROS1>3.0.CO;2-L","article-title":"Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen","volume":"30","author":"Xue","year":"1997","journal-title":"Prostate"},{"key":"10.1016\/j.trecan.2026.07.006_bb0435","doi-asserted-by":"crossref","first-page":"6435","DOI":"10.1158\/0008-5472.CAN-05-0133","article-title":"Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy","volume":"65","author":"Machlenkin","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.07.006_bb0440","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00262-010-0820-6","article-title":"HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase","volume":"59","author":"Olson","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2026.07.006_bb0445","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/2159-8290.CD-24-1213","article-title":"Recurrent immunogenic neoantigens and their cognate T-cell receptors in treatment-resistant metastatic prostate cancer","volume":"16","author":"Gumpert","year":"2026","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.07.006_bb0450","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA approval agnostic of cancer site\u2014when a biomarker defines the indication","volume":"377","author":"Lemery","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.07.006_bb0455","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdy232","article-title":"Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study","volume":"29","author":"Hansen","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0460","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41391-024-00799-y","article-title":"A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and\/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis","volume":"28","author":"Mosalem","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.trecan.2026.07.006_bb0465","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001065","article-title":"Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA","volume":"8","author":"Barata","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.07.006_bb0470","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.07.006_bb0475","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1200\/PO.19.00383","article-title":"CDK12-mutated prostate cancer: clinical outcomes with standard therapies and immune checkpoint blockade","volume":"4","author":"Schweizer","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0480","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0485","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminoncol.2023.09.003","article-title":"PARP inhibitors for prostate cancer","volume":"51","author":"Longoria","year":"2024","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0490","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.07.006_bb0495","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004761","article-title":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial","volume":"10","author":"Fizazi","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.07.006_bb0500","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1158\/1078-0432.CCR-21-1483","article-title":"Novel redirected T-cell immunotherapies for advanced prostate cancer","volume":"28","author":"Dorff","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.07.006_bb0505","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ijc.11402","article-title":"Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients","volume":"107","author":"Schmittgen","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2026.07.006_bb0510","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1073\/pnas.0502101102","article-title":"Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase","volume":"102","author":"Davis","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2026.07.006_bb0515","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","article-title":"Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases","volume":"52","author":"Sweat","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.trecan.2026.07.006_bb0520","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/pros.21090","article-title":"Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer","volume":"70","author":"Wolf","year":"2010","journal-title":"Prostate"},{"key":"10.1016\/j.trecan.2026.07.006_bb0525","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/pros.23214","article-title":"Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response","volume":"76","author":"Junghans","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.trecan.2026.07.006_bb0530","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.2023.41.6_suppl.140","article-title":"Early results from a phase 1, multicenter trial of PSCA-specific GoCAR T cells (BPX-601) in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Stein","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0535","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ccell.2025.05.013","article-title":"CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma","volume":"43","author":"Stahl","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.07.006_bb0540","first-page":"368","article-title":"CAR-adapted PIK3CD base editing enhances T cell anti-tumor potency","volume":"7","author":"Bucher","year":"2026","journal-title":"Nat. Can."},{"key":"10.1016\/j.trecan.2026.07.006_bb0545","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.eururo.2025.02.001","article-title":"T-cell engagers in prostate cancer","volume":"87","author":"Hage Chehade","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0550","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a BiTE\u00ae immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.trecan.2026.07.006_bb0555","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","article-title":"A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.07.006_bb0560","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2026.01.020","article-title":"Macrophages: targets for next-generation cancer immunotherapy","volume":"44","author":"Sun","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.07.006_bb0565","first-page":"740","article-title":"Harnessing myeloid cell plasticity for cancer therapy","volume":"7","author":"Sanseviero","year":"2026","journal-title":"Nat. Can."},{"key":"10.1016\/j.trecan.2026.07.006_bb0570","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0575","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","article-title":"MDSC: markers, development, states, and unaddressed complexity","volume":"54","author":"Hegde","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2026.07.006_bb0580","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.07.006_bb0585","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41590-024-02029-y","article-title":"The heterogeneity of neutrophils in cancer and its implication for therapeutic targeting","volume":"26","author":"Eruslanov","year":"2025","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0590","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.immuni.2025.07.011","article-title":"From complexity to consensus: a roadmap for neutrophil classification","volume":"58","author":"Ng","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2026.07.006_bb0595","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41577-024-01062-0","article-title":"Defining myeloid-derived suppressor cells","volume":"24","author":"Akkari","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0600","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1469594","article-title":"VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2026.07.006_bb0605","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/2326-6066.CIR-18-0725","article-title":"Blockade of TIGIT\/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma","volume":"7","author":"Wu","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2026.07.006_bb0610","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0615","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1084\/jem.20101956","article-title":"Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells","volume":"208","author":"Molon","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2026.07.006_bb0620","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20042028","article-title":"Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers","volume":"201","author":"Bronte","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2026.07.006_bb0625","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170762","article-title":"Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target","volume":"133","author":"Ozbay Kurt","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2026.07.006_bb0630","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s10637-016-0420-1","article-title":"First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors","volume":"35","author":"Forero","year":"2017","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.trecan.2026.07.006_bb0635","first-page":"4441","article-title":"All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination","volume":"63","author":"Kusmartsev","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.07.006_bb0640","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","article-title":"IL-23 secreted by myeloid cells drives castration-resistant prostate cancer","volume":"559","author":"Calcinotto","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.07.006_bb0645","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nature13638","article-title":"Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer","volume":"515","author":"Di Mitri","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.07.006_bb0650","first-page":"803","article-title":"Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression","volume":"2","author":"Lopez-Bujanda","year":"2021","journal-title":"Nat. Can."},{"key":"10.1016\/j.trecan.2026.07.006_bb0655","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.ccell.2024.08.018","article-title":"Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer","volume":"42","author":"Cali","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.07.006_bb0660","first-page":"1102","article-title":"The Akt\/mTOR and MNK\/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells","volume":"4","author":"Brina","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.trecan.2026.07.006_bb0665","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1084\/jem.20061104","article-title":"Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function","volume":"203","author":"Serafini","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2026.07.006_bb0670","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1158\/0008-5472.CAN-21-1237","article-title":"The dawn of myeloid-derived suppressor cells: identification of arginase I as the mechanism of immune suppression","volume":"81","author":"Gabrilovich","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.07.006_bb0675","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1158\/1078-0432.CCR-14-3145","article-title":"TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients","volume":"21","author":"Hossain","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.07.006_bb0680","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ccell.2023.02.004","article-title":"Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer","volume":"41","author":"Bancaro","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.07.006_bb0685","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2026.07.006_bb0690","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.07.006_bb0695","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","article-title":"Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression","volume":"23","author":"Chen","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0700","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.it.2022.04.008","article-title":"Macrophage diversity in cancer revisited in the era of single-cell omics","volume":"43","author":"Ma","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0705","article-title":"A Phase 1 study combining pexidartinib, radiation therapy, and androgen deprivation therapy in men with intermediate- and high-risk prostate cancer","volume":"6","author":"Hamid","year":"2021","journal-title":"Adv. Radiat. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0710","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011422","article-title":"Conformation-sensitive targeting of CD18 depletes M2-like tumor-associated macrophages resulting in inhibition of solid tumor progression","volume":"13","author":"Han","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.07.006_bb0715","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","article-title":"Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment","volume":"39","author":"Kfoury","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.07.006_bb0720","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1158\/0008-5472.CAN-21-3360","article-title":"HER3 is an actionable target in advanced prostate cancer","volume":"81","author":"Gil","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.07.006_bb0725","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ccell.2020.06.005","article-title":"Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer","volume":"38","author":"Zhang","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.07.006_bb0730","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41698-025-01170-7","article-title":"CAR-macrophages in solid tumors: promise, progress, and prospects","volume":"9","author":"Alrehaili","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0735","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.07.006_bb0740","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-025-01743-w","article-title":"PSMA-targeted CAR-macrophages drive glycolytic reprogramming for enhanced prostate cancer immunotherapy","volume":"18","author":"Xu","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0745","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.celrep.2019.07.068","article-title":"Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer","volume":"28","author":"Di Mitri","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2026.07.006_bb0750","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12943-019-1087-y","article-title":"STING: a master regulator in the cancer-immunity cycle","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2026.07.006_bb0755","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41698-023-00364-1","article-title":"Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer","volume":"7","author":"Rolfo","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0760","article-title":"Trial watch: Toll-like receptor agonists for cancer therapy","volume":"2","author":"Vacchelli","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2026.07.006_bb0765","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.chembiol.2024.04.004","article-title":"Stimulating STING for cancer therapy: taking the extracellular route","volume":"31","author":"Li","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0770","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1196829","article-title":"Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models","volume":"14","author":"Papaevangelou","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.07.006_bb0775","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.immuni.2025.03.005","article-title":"Mitochondrial DNA released by senescent tumor cells enhances PMN-MDSC-driven immunosuppression through the cGAS-STING pathway","volume":"58","author":"Lai","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2026.07.006_bb0780","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","article-title":"A neutrophil response linked to tumor control in immunotherapy","volume":"186","author":"Gungabeesoon","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.07.006_bb0785","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ccell.2023.01.002","article-title":"Neutrophil-activating therapy for the treatment of cancer","volume":"41","author":"Linde","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.07.006_bb0790","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.07.006_bb0795","first-page":"501","article-title":"Spatial and maturity heterogeneity of tertiary lymphoid structures shapes immune microenvironment and progression in prostate cancer","volume":"5","author":"Wang","year":"2025","journal-title":"J. Natl. Cancer Cent."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326001627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326001627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:22:59Z","timestamp":1786738979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326001627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":159,"alternative-id":["S2405803326001627"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.07.006","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate cancer: evading immunity, inspiring therapy","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}